Saturday 17 October 2026
Export EOLS’s income statement to Excel — free account
Evolus, Inc.
EOLS Healthcare Drug Manufacturers Specialty & Generic
Evolus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $297.2 million, up 11.6% from fiscal 2024. In the quarter to June 2026, revenue grew 21.2%, EPS grew 55.6%, free cash flow grew 84.9% and total debt rose 7.75%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
7.10
0.47
−6.21%
Follow EOLS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 3 | 3 |
+8 more TTM periods Free account |
| 138.57% | 245.43% | 587.36% | 512.13% | ||
| (14.40%) | (20.01%) | (22.53%) | (26.11%) | ||
ROIC |
(14.47%) | (19.54%) | (29.51%) | (33.33%) | |
Return on Tangible Assets |
(46.48%) | (56.96%) | (70.76%) | (79.88%) | |
Average Days of Receivables |
71.95 | 63.16 | 67.18 | 64.41 | |
Free Cash Flow per Share |
(0.33) | (0.69) | (0.79) | (0.89) | |
Free Cash Flow |
(21.90) | (44.87) | (50.72) | (57.93) | |
Capital Expenditures |
(6.51) | (8.28) | (8.45) | (7.65) | |
| Other line items | |||||
Cash ROIC |
(12.80%) | (25.29%) | (28.68%) | (36.09%) | |
Accounts Receivable Turnover |
5.75 | 6.06 | 5.81 | 6.01 | |
Accounts Payable Turnover |
3.11 | 5.74 | 6.14 | 5.18 | |
Inventory Turnover |
3.13 | 5.88 | 5.12 | 3.99 | |
Average Days of Payables |
154.21 | 69.58 | 85.21 | 87.86 | |
Days of Inventory on Hand |
141.79 | 88.35 | 98.35 | 125.80 | |
Tax Rate |
0.02 | 0.02 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
3.05% | 3.18% | 3.22% | 2.98% | |
Selling, General and Administrative Expense of Revenue |
68.41% | 71.61% | 74.29% | 75.70% | |
Share Based Compensation of Revenue |
6.64% | 6.59% | 6.96% | 7.60% | |
Interest Coverage |
(1.15) | (1.26) | (1.66) | (1.93) | |
Operating CF/Net income |
0.45 | 0.84 | 0.82 | 0.86 | |
Depreciation/Fixed assets |
2.32 | 2.05 | 1.87 | 1.76 | |
Capex/Depreciation |
(0.56) | (0.76) | (0.84) | (0.85) | |
Revenue per Share |
4.80 | 4.63 | 4.61 | 4.42 | |
Operating CF per Share |
(0.23) | (0.56) | (0.66) | (0.78) | |
Capex per Share |
(0.10) | (0.13) | (0.13) | (0.12) | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.03 |
Columns are period end dates